Imfinzi (durvalumab; AstraZeneca) Drug Overview 2019

Figure 1: The author's drug assessment summary of Imfinzi for HCC
Figure 1: The author's assessment summary of key marketed and pipeline drugs for HCC
Figure 2: HCC total market value across the US, Japan, and five major EU markets, by country, 2018-27
Figure 4: HCC sales in Japan, 2018–27
Figure 5: HCC sales in the five major EU markets, by country, 2018–27
Figure 6: The author's drug assessment summary for Imfinzi in non-small cell lung cancer
Figure 7: Imfinzi sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 8: Imfinzi for head and neck cancer – SWOT analysis
Figure 6: Price sources and calculations, by country
Figure 7: The author's drug assessment summary of Cabometyx for HCC
Figure 9: Cabometyx sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
Figure 12: The author's drug assessment summary for Imfinzi in urothelial bladder cancer

Table 1: Imfinzi drug profile
Table 2: Trials of Imfinzi for HCC
Table 3: Imfinzi for HCC – SWOT analysis
Table 4: Imfinzi drug profile
Table 5: Imfinzi pivotal trial data in non-small cell lung cancer
Table 6: Imfinzi late-phase trial data in non-small cell lung cancer
Table 7: Imfinzi ongoing late-phase clinical trials in non-small cell lung cancer
Table 8: Imfinzi sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 9: Imfinzi patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 10: Imfinzi drug profile
Table 11: Imfinzi Phase III trials in head and neck cancer
Table 12: Imfinzi early-phase data in head and neck cancer
Table 13: Imfinzi sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 14: Imfinzi patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
Table 15: Imfinzi drug profile
Table 16: Imfinzi pivotal trial data in urothelial bladder cancer
Table 17: Imfinzi ongoing late-phase trials in urothelial bladder cancer